72 related articles for article (PubMed ID: 26493284)
1. Mutations in genes encoding PI3K-AKT and MAPK signaling define anogenital papillary hidradenoma.
Pfarr N; Sinn HP; Klauschen F; Flechtenmacher C; Bockmayr M; Ridinger K; von Winterfeld M; Warth A; Lorenz K; Budczies J; Penzel R; Lennerz JK; Endris V; Weichert W; Stenzinger A
Genes Chromosomes Cancer; 2016 Feb; 55(2):113-9. PubMed ID: 26493284
[TBL] [Abstract][Full Text] [Related]
2. Frequent PIK3CA-activating mutations in hidradenoma papilliferums.
Liau JY; Lan J; Hong JB; Tsai JH; Kuo KT; Chu CY; Sheen YS; Huang WC
Hum Pathol; 2016 Sep; 55():57-62. PubMed ID: 27184479
[TBL] [Abstract][Full Text] [Related]
3.
Goto K; Maeda D; Kudo-Asabe Y; Hibiya T; Hayashi A; Fukayama M; Ohashi K; Goto A
J Clin Pathol; 2017 May; 70(5):424-427. PubMed ID: 27742746
[TBL] [Abstract][Full Text] [Related]
4. Several genotypes, one phenotype: PIK3CA/AKT1 mutation-negative hidradenoma papilliferum show genetic lesions in other components of the signalling network.
Pfarr N; Allgäuer M; Steiger K; Weichert W; Schirmacher P; Noske A; Stenzinger A
Pathology; 2019 Jun; 51(4):362-368. PubMed ID: 31010589
[TBL] [Abstract][Full Text] [Related]
5. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
[TBL] [Abstract][Full Text] [Related]
6. Tubular, lactating, and ductal adenomas are devoid of MED12 Exon2 mutations, and ductal adenomas show recurrent mutations in GNAS and the PI3K-AKT pathway.
Volckmar AL; Leichsenring J; Flechtenmacher C; Pfarr N; Siebolts U; Kirchner M; Budczies J; Bockmayr M; Ridinger K; Lorenz K; Herpel E; Noske A; Weichert W; Klauschen F; Schirmacher P; Penzel R; Endris V; Stenzinger A
Genes Chromosomes Cancer; 2017 Jan; 56(1):11-17. PubMed ID: 27438523
[TBL] [Abstract][Full Text] [Related]
7. Molecular alterations in lesions of anogenital mammary-like glands and their mammary counterparts including hidradenoma papilliferum, intraductal papilloma, fibroadenoma and phyllodes tumor.
Konstantinova AM; Vanecek T; Martinek P; Kyrpychova L; Spagnolo DV; Stewart CJR; Portelli F; Michal M; Kazakov DV
Ann Diagn Pathol; 2017 Jun; 28():12-18. PubMed ID: 28648934
[TBL] [Abstract][Full Text] [Related]
8. No evidence of oncogenic KRAS mutations in squamous cell carcinomas of the anogenital tract and head and neck region independent of human papillomavirus and p16(INK4a) status.
Prigge ES; Urban K; Stiegler S; Müller M; Kloor M; Mai S; Ottstadt M; Lohr F; Wenz F; Wagner S; Wittekindt C; Klussmann JP; Hampl M; von Knebel Doeberitz M; Reuschenbach M
Hum Pathol; 2014 Nov; 45(11):2347-54. PubMed ID: 25257576
[TBL] [Abstract][Full Text] [Related]
9. High-resolution melting analysis as a sensitive prescreening diagnostic tool to detect KRAS , BRAF , PIK3CA , and AKT1 mutations in formalin-fixed, paraffin-embedded tissues.
Ney JT; Froehner S; Roesler A; Buettner R; Merkelbach-Bruse S
Arch Pathol Lab Med; 2012 Sep; 136(9):983-92. PubMed ID: 22938585
[TBL] [Abstract][Full Text] [Related]
10. Study of Selected BRCA1, BRCA2, and PIK3CA Mutations in Benign and Malignant Lesions of Anogenital Mammary-Like Glands.
Konstantinova AM; Shelekhova KV; Imyanitov EN; Iyevleva A; Kacerovska D; Michal M; Kazakov DV
Am J Dermatopathol; 2017 May; 39(5):358-362. PubMed ID: 28291131
[TBL] [Abstract][Full Text] [Related]
11. Adenomyoepitheliomas of the Breast Frequently Harbor Recurrent Hotspot Mutations in PIK3-AKT Pathway-related Genes and a Subset Show Genetic Similarity to Salivary Gland Epithelial-Myoepithelial Carcinoma.
Lubin D; Toorens E; Zhang PJ; Jaffer S; Baraban E; Bleiweiss IJ; Nayak A
Am J Surg Pathol; 2019 Jul; 43(7):1005-1013. PubMed ID: 31094929
[TBL] [Abstract][Full Text] [Related]
12. Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma.
Santarpia L; Myers JN; Sherman SI; Trimarchi F; Clayman GL; El-Naggar AK
Cancer; 2010 Jun; 116(12):2974-83. PubMed ID: 20564403
[TBL] [Abstract][Full Text] [Related]
13. Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers.
Lee SY; Kim MJ; Jin G; Yoo SS; Park JY; Choi JE; Jeon HS; Cho S; Lee EB; Cha SI; Park TI; Kim CH; Jung TH; Park JY
J Thorac Oncol; 2010 Nov; 5(11):1734-40. PubMed ID: 20881644
[TBL] [Abstract][Full Text] [Related]
14. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
15. Oncogenic mutations in extramammary Paget's disease and their clinical relevance.
Kang Z; Xu F; Zhang QA; Wu Z; Zhang X; Xu J; Luo Y; Guan M
Int J Cancer; 2013 Feb; 132(4):824-31. PubMed ID: 22821211
[TBL] [Abstract][Full Text] [Related]
16. Analysis of major known driver mutations and prognosis in resected adenosquamous lung carcinomas.
Wang R; Pan Y; Li C; Zhang H; Garfield D; Li Y; Ye T; Hu H; Luo X; Li H; Zhang Y; Zhang J; Zhou X; Shen L; Pao W; Sun Y; Chen H
J Thorac Oncol; 2014 Jun; 9(6):760-8. PubMed ID: 24481316
[TBL] [Abstract][Full Text] [Related]
17. Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers.
Liu Z; Hou P; Ji M; Guan H; Studeman K; Jensen K; Vasko V; El-Naggar AK; Xing M
J Clin Endocrinol Metab; 2008 Aug; 93(8):3106-16. PubMed ID: 18492751
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population.
Abubaker J; Jehan Z; Bavi P; Sultana M; Al-Harbi S; Ibrahim M; Al-Nuaim A; Ahmed M; Amin T; Al-Fehaily M; Al-Sanea O; Al-Dayel F; Uddin S; Al-Kuraya KS
J Clin Endocrinol Metab; 2008 Feb; 93(2):611-8. PubMed ID: 18000091
[TBL] [Abstract][Full Text] [Related]
19. Mutational analysis of PIK3CA, JAK2, BRAF, FOXL2, IDH1, AKT1 and EZH2 oncogenes in sarcomas.
Je EM; An CH; Yoo NJ; Lee SH
APMIS; 2012 Aug; 120(8):635-9. PubMed ID: 22779686
[TBL] [Abstract][Full Text] [Related]
20. High-throughput oncogene mutation profiling shows demographic differences in BRAF mutation rates among melanoma patients.
van den Hurk K; Balint B; Toomey S; O'Leary PC; Unwin L; Sheahan K; McDermott EW; Murphy I; van den Oord JJ; Rafferty M; FitzGerald DM; Moran J; Cummins R; MacEneaney O; Kay EW; O'Brien CP; Finn SP; Heffron CC; Murphy M; Yela R; Power DG; Regan PJ; McDermott CM; O'Keeffe A; Orosz Z; Donnellan PP; Crown JP; Hennessy BT; Gallagher WM
Melanoma Res; 2015 Jun; 25(3):189-99. PubMed ID: 25746038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
